𝔖 Bobbio Scriptorium
✦   LIBER   ✦

S1066 Oral Alpha-4 Integrin Inhibitor (AJM300) in Patients with Active Crohn's Disease — A Randomized, Double-Blind, Placebo-Controlled Trial

✍ Scribed by Masakazu Takazoe; Mamoru Watanabe; Takaaki Kawaguchi; Takayuki Matsumoto; Nobuhide Oshitani; Nobuo Hiwatashi; Toshifumi Hibi


Book ID
119430670
Publisher
Elsevier Science
Year
2009
Tongue
English
Weight
100 KB
Volume
136
Category
Article
ISSN
0016-5085

No coin nor oath required. For personal study only.


📜 SIMILAR VOLUMES


Randomized, double-blind, placebo-contro
✍ Bruce E. Sands; Eric W. Jacobson; Thomas Sylwestrowicz; Ziad Younes; Gerald Dryd 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 349 KB 👁 1 views

## Background: Interleukin-12 (il-12) and interleukin-23 (il-23) are inflammatory cytokines linked to the th-1 and th-17 phenotypes associated with crohn's disease (cd). we investigated the activity and safety of apilimod mesylate (formerly sta-5326), an oral il-12 and il-23 inhibitor, in patients